Freely Filtered 054: EMPA Kidney!

1

Introduction

00:00 • 2min

2

SGLT2 Inhibitor Cardiovascular Outcome Trials - What's the Secret?

02:18 • 4min

3

SGLT to Inhibitor Trials in Nephrology

06:15 • 5min

4

ACE Inhibitor Versus S-G-L-T to Inhibitors?

11:14 • 2min

5

EGFR 20 to 45 With No Albuminuria, and Diabetes or No Diabetes?

12:58 • 4min

6

Is This the Biggest IgA Trial?

17:02 • 3min

7

NEJM - Credence vs DAPPA-CKD?

20:05 • 2min

8

The Primary Outcomes of Progression of Kidney Disease

21:46 • 2min

9

SGLT2 - What's the Difference?

23:52 • 5min

10

Are You Done?

28:42 • 2min

11

SGLT Two Inhibitors in COVID

30:56 • 3min

12

Euglycemic Decay in Non-Diabetic Patients

33:39 • 2min

13

Do They Mean an Adverse Event During the Placebo Phase?

36:00 • 2min

14

Is There a Problem With Randomization?

37:35 • 4min

15

The First Formal Interminalysis Trial

41:59 • 3min

16

The CKD Trials

45:14 • 3min

17

Diabetes and Albuminuria - Is There a Treatment Effect?

48:33 • 2min

18

SGLT 2 Inhibitors in Diabetes and CKD

50:36 • 2min

19

The Heterogeneity Coefficient

52:54 • 3min

20

The Slope of the EGFR Change

55:48 • 4min

21

The Long Term Slope in Non Diabetic Kidney Disease

01:00:16 • 2min

22

Is There a Higher Risk of Serious Hyperkalemia?

01:01:58 • 2min

23

Is There a Risk of Serious UTI?

01:03:56 • 2min

24

The UTI Is a Real Issue, Isn't It?

01:05:34 • 2min

25

Is There a Risk of Amputation in DAPA CKD?

01:07:47 • 3min

26

Is It a Supplement or a Drug?

01:10:40 • 3min

27

Dialysis Reduces Progression of Kidney Disease

01:14:06 • 2min

28

The Big Pushes Now Beyond Us It's Beyond Us Nephrologists

01:16:07 • 2min

29

Is There a GFR of 20 in Kidney Disease?

01:18:33 • 2min

30

AstraZeneca's Farcega Direct to Consumer Ads for CKD

01:20:36 • 4min

31

The Peripheral on Amazon Prime

01:24:45 • 2min

32

The Martian and Project Hail Mariots by the Same Author That Written March in There

01:26:49 • 4min